PURPOSE: The relationship between plasma lipid levels and neoplastic diseases is still unclear. The aim of this study was to analyse the lipid profile of individuals with non-Hodgkin's lymphoma (NHL) or prostate carcinoma (CaP) and to follow serum lipid levels changes in NHL patients according to their response to chemotherapy. PATIENTS AND METHODS: Forty-seven patients with NHL, 57 patients with CaP, two control groups composed of 29 and 43 age- and sex-matched healthy adults, related to NHL and CaP patients, respectively, were included in the study. Follow-up studies of NHL patients were carried out after the 3rd and 6th cycle of chemotherapy. RESULTS: Initial plasma cholesterol (Chol), HDL-cholesterol (HDL-Chol) and phospholipids (PL) values were significantly lower in patients with NHL or CaP than in controls. Following chemotherapy, we noticed a progressive increase in lipid levels in NHL patients with complete remission (CR) and stable disease (SD), and further decrease in patients with the disease progression. CONCLUSION: Decreased plasma Chol, HDL-Chol and PL levels of patients with NHL or CaP can be considered as non-specific prognostic parameters in patients with these malignancies.
PURPOSE: The relationship between plasma lipid levels and neoplastic diseases is still unclear. The aim of this study was to analyse the lipid profile of individuals with non-Hodgkin's lymphoma (NHL) or prostate carcinoma (CaP) and to follow serum lipid levels changes in NHLpatients according to their response to chemotherapy. PATIENTS AND METHODS: Forty-seven patients with NHL, 57 patients with CaP, two control groups composed of 29 and 43 age- and sex-matched healthy adults, related to NHL and CaP patients, respectively, were included in the study. Follow-up studies of NHLpatients were carried out after the 3rd and 6th cycle of chemotherapy. RESULTS: Initial plasma cholesterol (Chol), HDL-cholesterol (HDL-Chol) and phospholipids (PL) values were significantly lower in patients with NHL or CaP than in controls. Following chemotherapy, we noticed a progressive increase in lipid levels in NHLpatients with complete remission (CR) and stable disease (SD), and further decrease in patients with the disease progression. CONCLUSION: Decreased plasma Chol, HDL-Chol and PL levels of patients with NHL or CaP can be considered as non-specific prognostic parameters in patients with these malignancies.
Authors: Xinchun Zhou; Thomas J Lawrence; Zhi He; Charles R Pound; Jinghe Mao; Steven A Bigler Journal: Exp Mol Pathol Date: 2011-11-11 Impact factor: 3.362
Authors: Jonathan S Rink; Shuo Yang; Osman Cen; Tim Taxter; Kaylin M McMahon; Sol Misener; Amir Behdad; Richard Longnecker; Leo I Gordon; C Shad Thaxton Journal: Mol Pharm Date: 2017-10-03 Impact factor: 4.939
Authors: Zorica Cvetković; Vesna Vučić; Bora Cvetković; Ivana Karadžić; Marija Ranić; Marija Glibetić Journal: Med Oncol Date: 2013-10-02 Impact factor: 3.064